Literature DB >> 8641970

Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness.

T Hasebe1, H Tsuda, S Hirohashi, Y Shimosato, M Iwai, S Imoto, K Mukai.   

Abstract

Histological examination of invasive ductal carcinoma of the breast often demonstrates the presence of an extensive central fibrotic focus (FF). The clinicopathological significance of the FF, or scar, in primary invasive ductal carcinoma is still ambiguous. One hundred and fifty-three cases of invasive ductal carcinoma (IDC) were classified into two groups, those with and those without FF. The differences in frequency of immunohistochemically detected overexpression of c-erbB-2 protein and nuclear accumulation of p53 protein, and the labeling index of proliferating cell nuclear antigen (PCNA), as well as histopathological parameters were compared between these two groups. IDCs smaller than 50 mm with FF showed a higher frequency of high-grade tumors, a higher frequency of lymph node metastasis, and a significantly higher frequency of c-erbB-2 protein overexpression than those without FF. In tumors of 20 mm or less, the incidence of nuclear accumulation of p53 protein was significantly higher in tumors with than those without FF. Tumors with FF showed a significantly higher PCNA labeling index than those without FF, regardless of tumor size. The present results indicate that the presence of FF is an important clinicopathological parameter associated with a higher degree of malignancy in IDCs, especially those smaller than 50 mm. Therefore, dividing IDCs into those with and those without FF appears to be meaningful clinicopathologically.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641970      PMCID: PMC5921099          DOI: 10.1111/j.1349-7006.1996.tb00234.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  23 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

2.  Breast carcinoma. Aspects of early stages, progression and related problems.

Authors:  F Linell; O Ljungberg; I Andersson
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1980

3.  Long-term prognosis of scar and non-scar cancers of the breast.

Authors:  S Toikkanen; H Joensuu
Journal:  APMIS       Date:  1990-11       Impact factor: 3.205

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

Authors:  R Silvestrini; E Benini; M G Daidone; S Veneroni; P Boracchi; V Cappelletti; G Di Fronzo; U Veronesi
Journal:  J Natl Cancer Inst       Date:  1993-06-16       Impact factor: 13.506

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score.

Authors:  S R Tahan; D S Neuberg; A Dieffenbach; L Yacoub
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

8.  Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer.

Authors:  S Aaltomaa; P Lipponen; S Papinaho; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Platelet-derived growth factor (BB homodimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair.

Authors:  G F Pierce; J E Tarpley; D Yanagihara; T A Mustoe; G M Fox; A Thomason
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

Review 10.  Follow-up study of HER-2/neu amplification in primary breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

View more
  15 in total

1.  Evaluation of the R2* value in invasive ductal carcinoma with respect to hypoxic-related prognostic factors using iterative decomposition of water and fat with echo asymmetry and least-squares emission (IDEAL).

Authors:  Mari Miyata; Takatoshi Aoki; Shohei Shimajiri; Atsuji Matsuyama; Shunsuke Kinoshita; Masami Fujii; Takefumi Katsuki; Yuzuru Inoue; Yoshika Nagata; Yuko Tashima; Yukunori Korogi
Journal:  Eur Radiol       Date:  2017-04-11       Impact factor: 5.315

2.  Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer.

Authors:  Young Ju Jeong; Sung Hwan Park; Sung Hee Mun; Sang Gyu Kwak; Sun-Jae Lee; Hoon Kyu Oh
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

Review 3.  In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer.

Authors:  Bo Ri Seo; Peter DelNero; Claudia Fischbach
Journal:  Adv Drug Deliv Rev       Date:  2013-12-02       Impact factor: 15.470

4.  An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.

Authors:  Agnieszka K Witkiewicz; Abhijit Dasgupta; Federica Sotgia; Isabelle Mercier; Richard G Pestell; Michael Sabel; Celina G Kleer; Jonathan R Brody; Michael P Lisanti
Journal:  Am J Pathol       Date:  2009-05-01       Impact factor: 4.307

5.  C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development.

Authors:  Isadora F G Sena; Beatriz G S Rocha; Caroline C Picoli; Gabryella S P Santos; Alinne C Costa; Bryan O P Gonçalves; Ana Paula V Garcia; Maryam Soltani-Asl; Leda M C Coimbra-Campos; Walison N Silva; Pedro A C Costa; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Rodrigo R Resende; Debora Heller; Geovanni D Cassali; Akiva Mintz; Alexander Birbrair
Journal:  Histochem Cell Biol       Date:  2021-05-18       Impact factor: 4.304

6.  Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.

Authors:  Ying Chen; Tor A Klingen; Elisabeth Wik; Hans Aas; Einar Vigeland; Knut Liestøl; Øystein Garred; Jan Mæhlen; Lars A Akslen; Jon Lømo
Journal:  Diagn Pathol       Date:  2014-12-19       Impact factor: 2.644

7.  The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.

Authors:  Shin Saito; Kazue Morishima; Takashi Ui; Hiroko Hoshino; Daisuke Matsubara; Shumpei Ishikawa; Hiroyuki Aburatani; Masashi Fukayama; Yoshinori Hosoya; Naohiro Sata; Alan K Lefor; Yoshikazu Yasuda; Toshiro Niki
Journal:  BMC Cancer       Date:  2015-02-25       Impact factor: 4.430

8.  Characterisation of fibrosis in chemically-induced rat mammary carcinomas using multi-modal endogenous contrast MRI on a 1.5T clinical platform.

Authors:  Neil P Jerome; Jessica K R Boult; Matthew R Orton; James A d'Arcy; Ashutosh Nerurkar; Martin O Leach; Dow-Mu Koh; David J Collins; Simon P Robinson
Journal:  Eur Radiol       Date:  2017-10-16       Impact factor: 5.315

9.  Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer.

Authors:  Yoshinori Ino; Rie Yamazaki-Itoh; Seiji Oguro; Kazuaki Shimada; Tomoo Kosuge; Jan Zavada; Yae Kanai; Nobuyoshi Hiraoka
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

10.  Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4.

Authors:  Ubaldo E Martinez-Outschoorn; Joseph M Curry; Ying-Hui Ko; Zhao Lin; Madalina Tuluc; David Cognetti; Ruth C Birbe; Edmund Pribitkin; Alessandro Bombonati; Richard G Pestell; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2013-07-08       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.